H. Lee Moffitt Cancer Center & Research Institute
Boosting Immune Activity in the Fight Against Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States, and there is a lack of effective treatments for this disease. We recently found that a drug called ACY241, when administered in an animal model of NSCLC, promoted positive changes in the immune cells within the tumors. We will study how this drug evokes these changes in immune cells and determine if leveraging its immune-enhancing activity will be more effective than existing treatments when combined with other drugs that impair the activity of immune-suppressing T cells. This research could lead to new strategies to combat lung cancer.